Pharmacotherapy of bladder cancer – practice and prospects

Bibliography

• ZIELINSKI J: Nowotwory pecherza moczowego. In: Onkologia Urologiczna. Zieliski J (Ed.) PZWL Warszawa (1986):120–194.
   Google Scholar
• FERLAYJ, BRAY F, SANKILA R, PARKIN DM: Cancer incidence, mortality and prevalence in the European Union. Lyon: IARC Press. (1999).
   Google Scholar
• COLEMAN MP, ESTENE J, DAMIECKI P, ARSLAN A, RENARD H: Trends in cancer incidence and mortality. Lyon: IARC Press. Pub. no. 121. (1993).
   Google Scholar
• CASTELAO JE, YUAN JM, SKIPPER PL et al.: Gender- and smoking-related bladder cancer risk. Nati Cancer Inst. (2001) 93:538–545.
   PubMed Web of Science ®Google Scholar
• •Interesting epidemiology study showing that women are more susceptible to carcinogens in cigarette smoke.
   Google Scholar
• WRONKOWSKI Z, ZWIERKO M, CHMIELARCZYK W: Epidemiologia nowotworów zlosliwych w Polsce. Przewodnik Lekarza, Dodatek Onkologiczny (2000) (Suppl.):12–14.
   Google Scholar
• MICHELI A, FRANCISCI S, KROGH V, ROSSI AG, CROSIGNANI P: Cancer prevalence in Italian cancer registry areas: the ITAPREVAL study. ITAPREVAL Working Group. Tumouri (1999) 85:309–369.
   PubMedGoogle Scholar
• BERRINO F, CAPOCACCIA R, ESTENE J et al.: Survival of cancer patients in Europe. The Eurocare-II Study. Lyon: IARC Press. Publ. no. 151. (1999).
   Google Scholar
• COLEMAN MP, BABB P, DAMIECKI P et al.: Cancer survival trends in England and Wales, 1971–1995: deprivation and NHS Region. Studies in medical and population subjects. London: The Stationary Office. (1999).
   Google Scholar
• HENEY NM, AHMED S, FLANAGAN MJ et al: Superficial bladder cancer: progression and recurrence. J. Urol. (1983) 130:1083–1086.
   PubMed Web of Science ®Google Scholar
• HERR HW: Intravesical BCG: current results, natural history and implications for urothelial cancer prevention. Biochem. (1992) 161 (Suppl.) :112–119.
   Google Scholar
• LAMM DL, RIGGS DR, TRAYNELIS CL, NSEYO UO: Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. Urol. (1995) 153:1444–1450.
   Google Scholar
• LAMM DL, VAN DER MEIJDEN AP, AKAZA H et al.: Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses? Int.j Urol. (1995) 2(Suppl.):23–35.
   Google Scholar
• HERR HW, SCHWALB DM, ZHANG ZF et al.: Intravesical bacillus Calmette-Guerin therapy prevents tumour progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J. Cliii. Oncol. (1995) 13:1404–1408.
   PubMed Web of Science ®Google Scholar
• •Long-term results of intravesical immunotherapy showing clear clinical benefit.
   Google Scholar
• NEWLING DW, HETHERINGTON J, SUNDARAM SK, ROBINSON MR, KISBENEDEK L: The use of valrubicin for the chemoresection of superficial bladder cancer - a marker lesion study. Europ. Urol. (2001) 39:643–647.
   PubMed Web of Science ®Google Scholar
• O'DONNEL MA, KROHN J, DE WOLF WC: Salvage intravesical therapy with interferon-alpha2b plus low dose bacillus Calmette-guerin is effective in patients with superficial bladder cancer in whom bacillus calmette-guerin alone previously failed.' Urol. (2001) 166:1300–1305.
   PubMedGoogle Scholar
• MURRAY PJ, ALDOVINI A, YOUNG RA: Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guerin strains that secrete cytokines. Proc. Natl. Acad. Sri. USA. (1996) 93:934–939.
   PubMed Web of Science ®Google Scholar
• ••An article showing the elegant way ofimproving the efficacy of the BCG vaccine.
   Google Scholar
• CLINTON SK, CANTO E, O'DONNELL MA: Interleuldn-12. Oportunities for the treatment of bladder cancer. Urol. Clin. North. Am. (2000) 27:147–155.
   PubMedGoogle Scholar
• BRETSCHER PA: A strategy to improve the efficacy of vaccination against tuberculosis and leprosy. Inonunol. Today (1992) 13:342–345.
   PubMedGoogle Scholar
• ••Interesting review discussing newapproaches to BCG irmrtunotherapy.
   Google Scholar
• FILION MC, PHILIPS NC: Therapeutic potential of mycobacterial cell wall-DNA complexes. Expert Opin. Invest. Drugs (2001) 10:2157–2165.
   PubMed Web of Science ®Google Scholar
• NISHIYAMA T, TACHIBANA M, HORIGUCHI Y et al: Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin. Cancer Res. (2001) 7:23–31.
   PubMedGoogle Scholar
• ••Dendritic cells raised a great enthusiasmbut so far only a few investigators were able to introduce them successfully into the clinic.
   Google Scholar
• SAINT F, PATARD JJ, MAILLE P et al:Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus calmette-guerin treatment for superficial bladder cancer. J. Urol (2002) 167:364–367.
   PubMed Web of Science ®Google Scholar
• SAINT F, PATARD JJ, MAILLE Pet al.: Thelper lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-guerin for supreficial bladder cancer." Urol (2001) 166:2142–2147.
   Google Scholar
• VAN RHIJN BW, LURKIN I, KIRKELS WJ, VAN DER KWAST TH, ZWARTHOFF EC: Microsatellite analysis - DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a Phase II trial. Cancer (2001) 15:768–775.
   Google Scholar
• JONES PA, DROLLER MJ: Pathways of development and progression in bladder cancer: new correlations between clinical observations and molecular mechanisms. Semin. Um' (1993) 11:177–192.
   Google Scholar
• SCHULTZ PK, HERR HW, ZHANG ZF et al.: Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. I Clin. Oncol (1994) 12:1394–1401.
   PubMedGoogle Scholar
• HERMANSEN DK, REUTER VE, WHITMORE WFJ, FAIR WR, MELAMED MR: Flow cytometry and cytology as response indicators to M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Urol (1988) 140:1394–1396.
   Google Scholar
• SHIGYO M, SUGANO K, TOBISU K, TSUKAMOTO T, SEKIYA T, KAKIZOE T: Molecular follow-up of newly diagnosed bladder cancer using urine samples. j Urol (2001) 166:1280–1285.
   PubMed Web of Science ®Google Scholar
• HUDSON MA, HERR HW: Carcinoma in situ of the bladder. J. Urol (1995) 153:564–572.
   PubMed Web of Science ®Google Scholar
• TORTI FM, LUM BL: The biology and treatment of superficial bladder cancer. J. Clin amyl (1984) 2:505–531.
   Google Scholar
• LACOMBE L, DALBAGNI G, ZHANG ZF et al.: Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guerin therapy: correlation to clinical outcome. I Clin. °flea. (1996) 14:2646–2652.
   Google Scholar
• ••An article showing how to combinemolecular oncology with clinical practice.
   Google Scholar
• STEIN JP, GROSSFELD GD, GINSBERG DA et al: Prognostic markers in bladder cancer: a contemporary review of the literature. J. Urol (1998) 160:645–659.
   PubMed Web of Science ®Google Scholar
• STEIN JP, LIESKOWSKY G, COTE R et al.: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients.j Clin. amyl (2001) 19.
   Google Scholar
• POULSEN AL, HORN T, STEVEN K: Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall." Urol (1998) 160:2015–2019.
   PubMed Web of Science ®Google Scholar
• HERR HW, DONAT SM: Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy. Llml (2001) 165:65–66.
   Google Scholar
• VIEWEG J, GSCHWEND JE, HERR HW, FAIR WR: The impact of primary stage on survival in patients with lymph node positive bladder cancer." Urol (1999) 161:72–76.
   PubMed Web of Science ®Google Scholar
• MILLS RD, TURNER WH, FLEISCHMANN A, MARK WALDER R, THALMANN GN, STUDER UE: Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy. Urol (2001) 166:19–23.
   Google Scholar
• •Results of this analysis shows that patients with micrometastases in lymph nodes benefit from meticulous lymphadenectomy.
   Google Scholar
• STERNBERG CN, CALABRO F: Neo-adjuvant chemotherapy in invasive bladder cancer. World J. Urol (2001) 19:94–98.
   PubMedGoogle Scholar
• SYLVESTER R, STERNBERG C: The roleof adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. Ann. Oncol (2000) 11:851–856.
   PubMed Web of Science ®Google Scholar
• INTERNATIONAL COLLABORATION OF TRIALISTS: Neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy for muscle-invasive bladder cancer - a randomized controlled trial. Lancet (1999) 354:533–540.
   PubMedGoogle Scholar
• ••Results of the largest trial of neoadjuvantchemotherapy so far. Available from www.dinicaltrials.gov.
   Google Scholar
• NATALE RB, GROSSMAN HB, BLUMENSTEIN B et al.: SWOG 8710 (INT-0080): randomized Phase III trial of neoadjuvant MVAC + cystectomy versus cystectomy alone in patients with locally advanced bladder cancer. Proc. Natl. Acad. Sci. USA (2001) 20:2a. Abstract.
   Google Scholar
• •Very promising results of neoadjuvant chemotherapy published as an abstract.
   Google Scholar
• MILLIKAN R, DINNEY C, SWANSON D et al.: Integrated Therapy for locally advanced bladder cancer: adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. I Clin. OncoL (2001) 19:4005–4013.
   PubMed Web of Science ®Google Scholar
• ••Thorough evaluation of neoadjuvantchemotherapy in advanced but still operable bladder cancer.
   Google Scholar
• SPLINTER TA, SCHER HI, DENIS L et al.: The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer-Genitourinary Group. j. Urol (1992) 147:606–608.
   Google Scholar
• HERR HW, BAJORIN DF, SCHER HI: Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J. Clin. amyl (1998) 16:1298–1301.
   Google Scholar
• VON DER MAASE H, HANSEN SW, ROBERTS JT et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubcin and cisplatin in advanced or metastatic bladder cancer: results of a large randomized, multinational, multicenter, Phase III staudy. Clin. amyl (2000) 17:3068–3077.
   Google Scholar
• ••The largest Phase III study of the role ofchemotherapy in palliative setting so far.
   Google Scholar
• STERNBERG CN, DE MULDER PHM, SCHORNNAGEL JH et al: Randomized Phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicine and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumours: European Organization for Research and Treatment of Cancer Protocol No. 30924. J. Clin. anal. (2001) 19:2638–2646.
   Google Scholar
• KUBALL J, WEN SF, LEISSNER J et al: Successful adenovirus-mediated wild type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J. Clin. anal. (2002) 20:957–965.
   Google Scholar
• •Paper showing a proper way of conducting Phase I trial with a new-class drug: adenoviral vector carrying p53gene.
   Google Scholar
• STERNBERG CN, CALABRO F, PIZZOCARO G, MARINI L, SCHNETZER S, SELLA A: Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer (2001) 92:2993–2998.
   PubMed Web of Science ®Google Scholar
• •Promising results of a new chemotherapy regimen (gemcitabine—paditaxel) in advanced bladder cancer.
   Google Scholar
• MARCHETTI A, WANG L, MAGAR R et al.: Management of patients with Bacilli Calmette-Guerin-refractory carcinoma in situ of the urinary bladder: Cost implications of a clinical trial for valrubicin. Clin. Therap. (2000) 22:422–438.
   PubMed Web of Science ®Google Scholar
• •One of a few up-to-date cost analyses concerning treatments of refractory superficial bladder cancer.
   Google Scholar